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Abstract 13 
The illicit market for new psychoactive substances is forever expanding. Benzodiazepines 14 
and their derivatives are one of a number of groups of these substances and thus far their 15 
number has grown year upon year. As a consequence of the illicit nature of these compounds, 16 
there is a deficiency in the pharmacological data available for these ‘new’ benzodiazepines. A 17 
set of 69 benzodiazepine-based compounds was analysed to develop a quantitative structure-18 
activity relationship (QSAR) training set with respect to published binding values to GABAA
 19 
receptors. The QSAR model returned an R2 value of 0.90. The most influential factors were 20 
found to be the positioning of two H-bond acceptors, two aromatic rings and a hydrophobic 21 
group. A test set of nine random compounds was then selected for internal validation to 22 
determine the predictive ability of the model and gave an R2 value of 0.86 when comparing 23 
the binding values with their experimental data. The QSAR model was then used to predict 24 
the binding for 22 benzodiazepines that are classed as new psychoactive substances. This 25 
model will allow rapid prediction of the pharmacological activity of emerging 26 
benzodiazepines in a rapid and economic way, compared with lengthy and expensive in 27 
vitro/in vivo analysis. 28 
29 
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Introduction 32 
Benzodiazepines and their derivatives are routinely prescribed for a variety of medical 33 
conditions as anxiolytic, anti-insomnia and anti-convulsant drugs, acting on the gamma-34 
aminobutyric acid type A (GABAA) receptor [1, 2]. The endogenous neurotransmitter for the 35 
GABAA receptor is gamma-aminobutyric acid (GABA), the binding of which reduces the 36 
excitability of the cell [3]. Benzodiazepines potentiate the response of the GABAA receptor to 37 
GABA which results in far less cellular excitability which,  in physiological terms, results in 38 
sedation and relaxation [1]. 39 
In these circumstances benzodiazepines are medically beneficial by alleviating stress and 40 
agitation in patients through their anxiolytic effects. However, as a result of their 41 
psychoactive effects, benzodiazepines have a long history of abuse and are often illicitly 42 
obtained [4-6].  In more recent years a steady stream of benzodiazepines have appeared on 43 
the illicit market that have either been newly-synthesised or are licensed as prescription drugs 44 
in another country but not in the home country [7-10]. These are termed ‘new psychoactive 45 
substances’ [11, 12]. The majority of these emerging benzodiazepines have not undergone 46 
standard pharmaceutical trials and can be quite variant in their effects and potentially 47 
dangerous in their activity [13]. Although relatively safe when used as medically prescribed, 48 
concurrent use of benzodiazepines and opioids (either prescribed or abused) can lead to 49 
respiratory depression and death [4, 14, 15]. When benzodiazepines are not carefully 50 
prescribed and monitored, they can cause a variety of side effects including tolerance and 51 
dependency if taken long-term and sudden withdrawal can cause medical problems including 52 
anxiety and insomnia [16-18]. These new psychoactive substance (NPS) benzodiazepines 53 
have already been reported in a number of overdose cases, driving under the influence of 54 
drugs (DUID) cases and hospital admissions [8, 19-22]. The lack of control and safety over 55 
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these illicit benzodiazepines is a prevalent issue and it is likely that it will become an even 56 
more worrying trend as their misuse continues to rise.  57 
Benzodiazepines are a diverse group of psychoactive compounds with a central structural 58 
component consisting of a benzene ring and a diazepine ring (Figure 1). A whole host of 59 
derivatives exist which include triazolobenzodiazepines, thienotriazolobenzodiazepines and 60 
imidazobenzodiazepines (see Supplementary Information Figure S1 and Table S1).  61 
Quantitative structure-activity relationship (QSAR) models attempt to correlate molecular 62 
structure to biological activity, often using a variety of molecular descriptors such as 63 
physiochemical, topological, electronic and steric properties [23]. Typically, a set of 64 
compounds whose biological activity is known is used to create a ‘training’ dataset and a 65 
model. This model can then be used to predict the unknown biological activity of compounds 66 
with a similar structure or to explore the structural features that are important for the specific 67 
biological activity in question. QSAR has been extensively used within the pharmaceutical 68 
industry for a number of years [24, 25]. In terms of applications towards new psychoactive 69 
substances, the predictive power of QSAR has been mainly applied to cannabinoid binding to 70 
the CB1 and CB2 receptors [26-28] but has also been used to examine the biological activity 71 
of hallucinogenic phenylalkylamines [29], the binding of phenylalkylamines, tryptamines and 72 
LSD to the 5-HT2A receptor [30] and methcathinone selectivity for dopamine (DAT), 73 
norepinephrine (NAT) and serotonin transporters (SERT) [31].  Currently, the majority of 74 
novel benzodiazepines have not been analysed to determine their physicochemical and 75 
biological properties as this would require a substantial investment in both time and money. It 76 
is for this reason that a fast, yet economical method to predict their properties is desirable. 77 
QSAR has previously been applied to benzodiazepines to predict bioavailability, absorption 78 
rate, clearance, half-life and volume of distribution for a group of benzodiazepines. This 79 
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study included phenazepam [32], a benzodiazepine that appeared as an NPS in 2007 [33].  80 
Other benzodiazepines (such as etaziolam) only appeared as new psychoactive substances in 81 
the years following the publication of this study. Furthermore, the application of a QSAR 82 
methodology has been used for modelling post-mortem redistribution of benzodiazepines 83 
where a good model was obtained (R2 = 0.98) in which energy, ionisation and molecular size 84 
were found to exert significant impact [34]. Quantitative structure-toxicity relationships  85 
(QSTR) have been used to correlate the toxicity of benzodiazepines to their structure in an 86 
attempt to predict the toxicity of these compounds  [35]. More recently, a study reported the 87 
use of QSTR whereby it was concluded that it is possible to identify structural fragments 88 
responsible for toxicity (the presence of amine and hydrazone substitutions as well as 89 
saturated heterocyclic ring systems resulted in a greater toxicity) and potentially use this 90 
information to create new, less toxic benzodiazepines for medical use [36].  91 
Various QSAR models have been used to correlate benzodiazepine structure to GABAA 92 
receptor binding and tease apart the complex relationship between various substituents and 93 
their effect on activity [37-42] although none have specifically attempted to predict binding 94 
values for benzodiazepines that are new psychoactive substances. 95 
In this study we focus on the relationship between the structure of characterised 96 
benzodiazepines and observed biological activity through receptor binding, expressed as the 97 
logarithm of the reciprocal of concentration (log 1/c) where c is the molar inhibitory 98 
concentration (IC50) required to displace 50 % of [3H]-diazepam from rat cerebral cortex 99 
synaptosomal preparations [40]. The purpose of this work is to create a QSAR model that can 100 
be used to predict the potential biological activity of the newly-emerging benzodiazepines to 101 
help understand, and therefore minimise their harmful potential in a faster time scale 102 
compared with in vitro/in vivo testing.  103 
5 
 
 104 
Methods and Materials 105 
Selection of the dataset 106 
The binding data for the benzodiazepines was used as obtained from the literature, 107 
experimentally determined using spectrometric measurements of [3H]-diazepam 108 
displacement [43]. Benzodiazepines were selected from four categories; 1,4-benzodiazepines, 109 
triazolobenzodiazepines, imidazobenzodiazepines and thienotriazolobenzodiazepines.  110 
Benzodiazepines that did not have definitive binding values (i.e. listed values were simply 111 
stated as >1000 or >5000) were excluded. For simplicity benzodiazepines with atypical atoms 112 
or substituents (e.g. Ro 07-9238 which contained a sodium atom and Ro 05-5065 which 113 
contained a naphthalene ring) were also excluded. Benzodiazepines that also had atypical 114 
substitutions (i.e. positions R6, R8 and R9 from Figure 1 which are not found in medically-115 
used benzodiazepines or indeed those that are new psychoactive substances) were also 116 
excluded. In total, 88 benzodiazepines were selected for the training dataset. 117 
QSAR/Software and Data Analysis Method 118 
The 88 benzodiazepines were converted from SMILES to 3D structures based on Merck 119 
Molecular Force Field (MMFF) atom type and force field optimisation. These compounds 120 
were then aligned by common substructure and confirmation to Ro 05-306. Subsequently, the 121 
aligned compounds were clustered by Atomic Property Fields (APF) to identify 122 
benzodiazepines with poor alignment. The APF method, designed by MolSoft, uses the 123 
assignment of a 3D pharmacophore potential on a continuously distributed grid using physio-124 
chemical properties of the selected compound(s) to classify or superimpose compounds. 125 
These properties include: hydrogen bond donors, acceptors, Sp2 hybridisation, lipophilicity, 126 
size, electropositivity/negativity and charge [44, 45]. Poorly aligned benzodiazepines 127 
identified by APF clustering were subjected to re-alignment using APF-based flexible 128 
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superimposition. At this point, 10 benzodiazepines with poor alignment were removed to 129 
improve model accuracy. (Supplementary Information Table 1S). 130 
From the remaining 78 aligned compounds, 9 compounds were selected using a random 131 
number generator based on atmospheric noise. These compounds were removed from the 132 
training set and used for final model validation. The residual 69 compounds were used as the 133 
training set to build a 3D QSAR model, as shown in Figure 2.  134 
The APF 3D QSAR method was used where, for each of the 69 aligned compounds, the 135 
seven physicochemical properties were calculated and pooled together. Based on the activity 136 
data obtained from literature and the 3D aligned structures for the known compounds, 137 
weighted contributions for each APF component were obtained to allow quantitative activity 138 
predictions for unknown compounds. The optimal weight distributions were assigned by 139 
partial least-squares (PLS) methodology, where the optimal number of latent vectors for PLS 140 
was established by leave-one-out cross-validation on the training set. Then the weighted 141 
contributions were added together. The 9 compounds for validation and unknown compounds 142 
were assigned predicted binding values by calculating their fit within the combined QSAR 143 
APF. Any unknown benzodiazepines were subjected to the conversion and alignment 144 
protocol before predicted binding data was obtained. The above steps were conducted using 145 
Molsoft’s ICM Pro software [46]. 146 
Further analysis of the PLS model fragment contributions from the 69 compounds was 147 
conducted using SPCI software. Here, a 2D QSAR model was built using the same PLS 148 
methodology as above. Additionally, a consensus model was created from averaging the 149 
predictions of PLS, gradient boosting, support vector machine and random forest modelling 150 
methods. The compounds were then subjected to automatic fragmentation and contribution 151 
calculations, which resulted in information on 11 key contributing groups [47]. Using Ligand 152 
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Scout with default settings, four ligand-based pharmacophore models were created using 153 
compounds with binding values of 6.0-9.0, 7.0-9.0, 8.0-9.0 and 8.5-9.0, as exemplified in 154 
Figure 3. 155 
Ten benzodiazepines that had the highest predicted binding values were docked into a 156 
modelled GABAA5 receptor using ICM software. The GABAA5 receptor model was generated 157 
by homology modelling, using the crystal structure of a human GABA(A)R-beta3 158 
homopentamer (PDB id 4COF) as a template. A pre-defined binding site containing co-159 
crystallised benzodiazepine is already present in the template, which was retained in the final 160 
model. Modeller software was used to generate the homology models [48]. The final chosen 161 
model was energy minimized using the ACEMD software [49]. The stereochemistry was 162 
checked using Procheck and ProSA software [50, 51]. The benzodiazepine in the allosteric 163 
binding site on the GABAA5 receptor was used as a chemical template to dock NPS-164 
benzodiazepines and the best-scoring conformations were analysed.  165 
The distances between principle physiochemical properties and their weights in the 166 
pharmacophore model were calculated using the software LigandScout [52]. 167 
Results and Discussion 168 
The data that was used to create the QSAR model (i.e. benzodiazepine structural substitutions 169 
and experimentally-observed binding values) is provided in the Supplementary Information 170 
(Table S1). 171 
From the pharmacophore model visualised in Figure 3 for highly bound benzodiazepines (log 172 
1/c of 8.0 – 9.0), it is evident that important binding features for the benzodiazepines were the 173 
positioning of two H-bond acceptors, two aromatic rings and a hydrophobic group all with 174 
weights of 1.0. 175 
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The predicted binding values are not presented here but are listed in Supplementary 176 
Information (Table S1). They can be visualised in Figure 4 as a plot of the observed binding 177 
value versus the predicted binding value.   178 
Nine compounds were selected at random from the QSAR training set and their binding 179 
values estimated using the model as a system of internal validation. These estimated values 180 
were then compared to the experimental binding values (Figure 5).  181 
The QSAR model was then used to predict the binding for 22 benzodiazepines that are 182 
classed as new psychoactive substances. The results are divided in to four categories 183 
depending upon the nature of the substitutions, as shown in Tables 1, 2, 3 and 4.  184 
Five compounds were present in the training dataset but have also appeared as new 185 
psychoactive substances; adinazolam, desalkylflurazepam, desmethylflunitrazepam 186 
(fonazepam), etizolam and meclonazepam. The experimental binding values from the 187 
literature and the predicted binding values are displayed in Table 5.  188 
The NPS-benzodiazepine with the highest predicted log 1/c value was flunitrazolam with 189 
8.88, closely followed by clonazolam with 8.86. However, based upon experimental data, 190 
meclonazepam with a log 1/c value of 8.92 (8.52 predicted) actually exhibited the greatest 191 
binding affinity. Only two benzodiazepines in the training set experimental values had a log 192 
1/c value of 8.92; these were meclonazepam and brotizolam with the rest falling below this 193 
point. In general, the limitations to this model are most likely caused by the small size of the 194 
data set. It is widely reported that QSAR models have poorer predictive capabilities with 195 
training sets under 100 compounds [53, 54]. Moreover, the diversity of substitutions within 196 
the small set of training compounds, created difficulties with APF superimposition and 197 
therefore may have reduced the accuracy of the model predictors. Secondary modelling with 198 
SPCI highlighted these limitations and demonstrated the existing dataset was less suitable for 199 
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PLS 2D QSAR modelling [47]. However, the consensus from multiple modelling methods 200 
improves the predictive power of the 2D QSAR model.  Additionally, as experimental errors 201 
in the training set are amplified both by the logarithmic scale and when calculating the 202 
weighted contributions, consistency and accuracy in the initial experimental values are 203 
essential for a strong QSAR model. Ideally, further improvements to the model could be 204 
made by using a larger training dataset with lower diversity yet this cannot be achievable as a 205 
consequence of limitations on literature data available. 206 
From these docking studies with the modelled GABAA5 receptor it can be seen that they only 207 
partially occupy the available volume at the allosteric binding site (exemplified in Figure 6 208 
for flunitrazolam). From the ten compounds that had the greatest binding affinity, four had 209 
non-bonded interactions with the T80 region within the receptor, two had non-bonded 210 
interactions with the K182 and S231 regions respectively. There were also stacking 211 
interactions with the Y96 region for four of the compounds. Therefore the possibility is that 212 
the binding is not completely optimal for these benzodiazepines and that with a modified 213 
chemical structure, a greater binding affinity could be theoretically possible. The reality 214 
exists that a benzodiazepine with an optimised binding affinity could emerge onto the illicit 215 
drugs market and could potentially (but not necessarily) exhibit a greater potency. 216 
The 10 compounds with the greatest binding affinity for the receptor are listed in Table 6 217 
(lower scores indicate a greater binding effect).  218 
There are 35 benzodiazepines and their derivatives currently subject to international control, 219 
30 of these compounds had binding values listed in the original source [43]. The average log 220 
1/c value for these 30 controlled compounds was 7.57. Out of these compounds, 43 % (13 out 221 
of 30) had a log 1/c value that was greater than 8.00. The average log 1/c value for the whole 222 
training dataset was 7.81 and 48 % of the compounds (33 out of 69) had a log 1/c value that 223 
was greater than 8.00. These values are fairly similar, however when comparing the results of 224 
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the benzodiazepines that are new psychoactive substances, the average log 1/c value that was 225 
predicted was 8.22 and 68 % of the compounds (15 out of 22) had a log 1/c value that was 226 
greater than 8.00. From this it is appears that benzodiazepines that are appearing as new 227 
psychoactive substances are more likely to have a greater binding affinity at the GABAA 228 
receptor. Whether this trend is deliberate is unclear.  229 
A log 1/c value of 7.88 was obtained for 4-chlorodiazepam (Ro 5-4864). This suggests a 230 
relatively high affinity for the GABAA receptor when compared with the log 1/c values for 231 
clinically-used benzodiazepines; the binding value for diazepam is 8.09 and 8.40 for 232 
triazolam. However it has been reported that the experimental value for 4-chlorodiazepam 233 
(Ro-4864) is actually 3.79 (i.e. an IC50 value of 160,500 nM) in one dataset when compared 234 
with a log 1/c of 7.80 for diazepam and 8.72 for triazolam in the same dataset [55]. There are 235 
obvious impracticalities with comparing different datasets as a result of differences in 236 
methods (e.g. the use of [3H]-diazepam versus [3H]-flunitrazepam as a radioligand), the 237 
differences in the species used (rat vs. mouse) and the differences in GABAA receptor 238 
expression between different brain homogenates. Despite this it is clear that 4-239 
chlorodiazepam observes an extremely low affinity for GABAA receptors and one that this 240 
model did not accurately predict. This most likely results from the deficit of compounds in 241 
the training dataset that had a similar substitution on the R4’ position of the phenyl ring. 242 
Indeed, this model focused upon the ‘classical’ 1,4-benzodiazepine, triazolobenzodiazepine, 243 
imidazobenzodiazepine and thienotriazolodiazepine substitutions. Substitutions on the R4’ 244 
position of the phenyl ring are known to exhibit strong steric repulsion at the GABAA 245 
receptor interface and therefore compound binding is severely inhibited [39] [56]. 4-246 
chlorodiazepam is an outlier and atypical benzodiazepine as it does not act upon the GABAA 247 
receptor; instead exerting its pharmacological effects through the translocator protein 18 kDa 248 
(TSPO), previously known as the peripheral benzodiazepine receptor [57, 58]. 249 
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 250 
The oxazolobenzodiazepine flutazolam, a prescription drug in Japan, had a predicted log 1/c 251 
binding value of 6.83 which seems extremely low compared with the other benzodiazepines 252 
in this dataset. To the best of the authors’ knowledge there exists no experimental GABAA 253 
receptor binding data for flutazolam. However other oxazolobenzodiazepines have low 254 
affinities for the GABAA receptor such as ketazolam with a log 1/c value of 5.89 [59] and 255 
oxazolam with a log 1/c value of 5.00 [60]. These log 1/c binding values are from additional 256 
sources – the previous paragraph discusses the difficulties in comparing binding values from 257 
different datasets. Nonetheless it is clear that oxazolobenzodiazepines exhibit a much lower 258 
affinity for the GABAA receptor.   If the value for flutazolam is correct then this QSAR 259 
model successfully predicted the low binding affinity of flutazolam despite having no 260 
oxazolobenzodiazepines in the training dataset which serves as an indicator to the potential 261 
strength of the model. 262 
Conclusions 263 
The emergence of benzodiazepines and their derivatives as new psychoactive substances 264 
necessitates the investigation of their pharmacological attributes. The use of a QSAR model 265 
is ideal to gain an understanding into the binding properties of these substances. In this work 266 
a QSAR model has been successfully developed to predict the binding data for NPS-267 
benzodiazepines. Benzodiazepines that have emerged as new psychoactive substances appear 268 
to have a greater binding affinity to GABAA receptors than those benzodiazepines that are 269 
used medically and are under international control. Whether this trend will continue is 270 
uncertain. Further in vitro work would allow the compilation of more data to improve the 271 
accuracy of this model. However, this model does allow a rapid estimation of the binding 272 
affinity of emerging benzodiazepines before more detailed studies can be carried out. 273 
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Tables 474 
Table 1. Structural information and predicted binding values for 1,4-benzodiazepines 475 
Name 
Substitutions Log 1/c 
predicted 
Basic structure 
R7 R1 R2' R3 
Diclazepam Cl CH3 Cl - 8.39 
 
Desalkylflurazepam Cl - F - 8.44 
Meclonazepam NO2 - Cl CH3 8.52 
Phenazepam Br - Cl - 8.12 
Desmethylflunitrazepam NO2 - F - 8.46 
3-hydroxyphenazepam Br - Cl OH 8.42 
Flubromazepam F - Br - 8.37 
Nifoxipam NO2 - F OH 8.63 
Cloniprazepam NO2 - Cl C3H5CH3 7.83 
Nimetazepam NO2 CH3 - - 7.87 
4-chlorodiazepama Cl CH3 - - 7.88 
a4-chlorodiazepam has a Cl substituted on the R4’ position of the phenyl ring 
 
 
  
Table 2. Structural information and predicted binding values for triazolobenzodiazepines 476 
 477 
 478 
 479 
 480 
Name 
Substitutions Log 1/c 
predicted 
Basic structure 
R8 R1 R2' R4 
Flubromazolam Br CH3 F - 8.77 
 
Clonazolam NO2 CH3 Cl - 8.86 
Flunitrazolam NO2 CH3 F - 8.88 
Bromazolam NO2 CH3 - - 8.25 
Adinazolam Cl CH3N(CH3)2 - - 7.18 
Pyrazolama Br CH3 - - 7.79 
Nitrazolam NO2 CH3 - - 8.34 
aPyrazolam has a 2-pyridyl ring at position 6 rather than a phenyl ring  
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Table 3. Structural information and predicted binding values for thienotriazolodiazepines 481 
Name 
Substitutions Log 1/c 
predicted 
Basic structure 
R9 R2 R2' 
Deschloroetizolam CH3 CH2CH3 - 7.96 
 
Etizolam CH3 CH2CH3 Cl 8.64 
Metizolam - CH2CH3 Cl 8.34 
 482 
 483 
Table 4. Structural information and a predicted binding value for an oxazolobenzodiazepine 484 
 485 
 486 
Name 
Substitutions Log 1/c 
predicted 
Basic Structure 
R10 R7 R2' 
Flutazolam Cl CH2CH2OH F 6.83 
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Table 5. Observed and predicted binding values for new psychoactive substances 487 
Compound 
Log 1/c 
observed 
Log 1/c 
predicted 
% (log 1/c obs.) / (log 1/c pred.) 
Adinazolam 6.87 7.18 95.9 % 
Desalkylflurazepam 8.70 8.44 103.1 % 
Desmethylflunitrazepam 
(fonazepam) 
8.82 8.46 104.3 % 
Etizolam 8.51 8.64 98.5 % 
Meclonazepam 8.92 8.52 104.7 % 
 488 
Table 6. Binding scores and molecular descriptors of the 10 compounds exhibiting the 489 
greatest binding affinity for the receptor 490 
 491 
Compound 
Name 
Score  Number 
of 
Atoms 
in 
ligand 
number of 
rotatable 
torsions 
Hydrogen 
Bond 
energy 
hydropho
bic energy 
in 
exposing 
a surface 
to water  
van der 
Waals 
interactio
n energy  
internal 
conformation 
energy of the 
ligand  
desolvation of 
exposed h-
bond donors 
and acceptors 
solvation 
electrostatics 
energy change 
upon binding  
potential of 
mean force 
score 
Flunitrazolam -17.9003 37 1 -1.55071 -6.12229 -27.3992 4.10324 10.7377 13.4407 -158.403 
Clonazolam -15.4617 37 1 -1.53992 -6.124 -27.9233 7.64508 11.6698 16.8309 -154.162 
Flubromazolam -18.2738 35 0 -1.61755 -6.89366 -25.8773 3.57746 11.0855 12.122 -151.357 
Etizolam -18.7025 38 1 -2.03733 -7.14073 -25.5154 7.89581 11.8052 11.0572 -101.516 
Nifoxipam -20.836 33 2 -5.90608 -4.9646 -22.352 6.0639 12.5432 13.905 -129.57 
Meclonazepam -13.4447 35 1 -2.27939 -5.98463 -21.8787 5.69717 10.6159 14.6192 -124.257 
Desmethylfluni
trazepam 
-15.5192 32 2 -0.82246 -5.27009 -26.2114 2.37454 10.376 11.0938 -144.474 
Desalkylfluraze
pam 
-21.7837 30 0 -2.01574 -5.82939 -27.462 0.691701 9.53716 11.4106 -154.372 
Diclazepam -16.8002 33 0 -0.60989 -6.76567 -25.688 2.00693 10.3028 10.9647 -121.093 
Metizolam -13.7614 35 1 -1.78622 -6.65559 -24.7768 3.51234 14.5321 12.8708 -138.056 
 492 
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Figures 505 
 506 
 507 
Figure 1: The basic structural formula for benzodiazepines considered in this work 508 
 509 
 510 
Figure 2: Alignment of 69 training set benzodiazepines shown in two orientations. 511 
20 
 
 512 
Figure 3: Pharmacophore model of 33 compounds with binding values 8.0-9.0  513 
 514 
 515 
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 516 
Figure 4: Literature (i.e. observed) binding values (log 1/c) vs. QSAR predicted binding 517 
values fit with a partial least squares (PLS) regression (R2 = 0.90).  518 
 519 
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 520 
Figure 5: Literature (i.e. observed) binding values (log 1/c) vs. QSAR predicted binding 521 
values for 9 compounds randomly selected for internal validation (R2 = 0.86).  522 
 523 
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 524 
 525 
Figure 6: Visualisation of the NPS-benzodiazepine flunitrazolam binding to the allosteric 526 
site of the GABAA5 receptor 527 
 528 
